In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

They also discovered that cigarette use declined among a subgroup of smokers in the study, lending weight to the hypothesis ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead this lucrative and fast-growing market. However, Novo Nordisk (NYSE ...

Novo Nordisk recently reported data from a phase 1b/2a clinical trial for the subcutaneous formulation of amycretin. The study enrolled 125 overweight or obese patients, with some receiving ...

The European Commission has granted marketing authorisation for Novo Nordisk’s adult diabetes ... daily basal insulin degludec in a soluble formulation with insulin aspart.

Novo Nordisk (NVO) stock jumped 12% in pre-market ... that we have previously seen with the oral formulation.” Amycretin is what’s known as a “unimolecular long-acting GLP-1 and amylin ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.